Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cholesterol drug could boost bone growth for dental implants

NCT ID NCT07692620

Disease control Sponsor: Maruwan Ali Alteer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether adding a simvastatin and platelet-rich fibrin (PRF) composite to a standard bone graft improves bone regeneration during dental implant surgery. The study enrolls adults aged 18–50 with a narrow jawbone (3–5 mm wide) who need an implant in the lower front jaw. Participants are randomly assigned to receive either a bone graft alone, a bone graft with PRF, or a bone graft with a simvastatin/PRF composite. The goal is to see which approach yields the best bone gain and implant stability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Simvastatin and Platelet-Rich Fibrin (PRF) composite
What this could lead to
If successful, this approach could improve bone regeneration and implant success in patients with insufficient jawbone width, reducing the need for more invasive grafting procedures.
What could go wrong
This is a small, early-stage trial with only 21 participants, so results may not apply broadly. The added benefits of simvastatin and PRF over standard bone grafting are uncertain, and there is a risk of infection, implant failure, or adverse reactions to the materials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Jun 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Horizontal alveolar ridge width of 3-5 mm. Vertical alveolar bone height of ≥11 mm. Edentulous site located in the mandibular anterior region. Absence of buccal bone undercuts. Male or female participants aged 18-50 years. Good general health and medically fit to undergo oral surgical procedures. Absence of periapical pathology at the intended implant site. Adequate crown height space to achieve a favorable crown-to-implant ratio. Willingness and ability to attend all scheduled follow-up visits. Provision of written informed consent. Exclusion Criteria: Uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus), active infection, bleeding disorders, or current anticoagulant therapy. Severe systemic diseases (e.g., uncontrolled hypertension or severe cardiovascular disease). Severe alveolar bone deficiencies not suitable for ridge splitting. Pregnancy or breastfeeding. Inability to comply with postoperative instructions or follow-up visits. Known allergy or hypersensitivity to simvastatin or study materials. Individuals from vulnerable populations unable to provide valid informed consent. Bruxism or other parafunctional oral habits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar ridge atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tooth Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar ridge atrophy Tooth loss

Contacts and locations

Locations

  • Faculty of Oral and Dental Surgery, Misr University for Science and Technology

    Cairo, Giza Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.